摘要：2025年11月8日- 10日，全球心血管领域的年度学术盛典 —— 美国心脏协会科学年会（2024 AHA）将在新奥尔良拉开帷幕，为全球医者打造沉浸式学术交流平台。作为大会核心亮点，组委会精心设置7场“最新科学研究（Late Breaking Science）
2025年11月8日- 10日，全球心血管领域的年度学术盛典 —— 美国心脏协会科学年会（2024 AHA）将在新奥尔良拉开帷幕，为全球医者打造沉浸式学术交流平台。作为大会核心亮点，组委会精心设置7场“最新科学研究（Late Breaking Science）专场”，届时将集中发布26项具有里程碑意义的心血管临床研究成果。
LBS.01 心脏代谢疾病治疗领域的突破性试验
北京时间：11月8日 21:30
DR10624, a First-In-Class, FGF21 Receptor /Glucagon Receptor /GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial
DR10624 II期随机试验的主要结果：在严重高甘油三酯血症患者中，首款FGF21受体/胰高血糖素受体/GLP-1受体三重激动剂DR10624可快速显著降低甘油三酯、致动脉粥样硬化脂质和肝脏脂肪水平
First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
I期临床试验：靶向ANGPTL3的CRISPR-Cas9基因编辑疗法的首次人体试验
Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial
VESALIUS-CV试验主要结果：依洛尤单抗对无心梗或卒中病史高心血管风险患者的影响
LBS.02 房颤术后管理中的抗血栓治疗困境
北京时间：11月9日 02:30
Appropriate Duration of Antiplatelet and Thrombotic Strategy after 12 Months in Patients with Atrial Fibrillation Treated with Drug-Eluting Stents
ADAPT AF-DES试验：置入药物洗脱支架的房颤患者术后12个月抗血小板和抗栓策略的适宜疗程
Short Dual Antithrombotic Therapy after PCI in Patients with Atrial Fibrillation: OPTIMA-AF trial
OPTIMA-AF试验：房颤患者PCI术后短期双联抗栓治疗
Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy
CLOSURE-AF试验：在高卒中及出血风险的房颤患者中，比较左心耳封堵术和药物治疗的疗效及安全性
The Need for Ongoing Oral Anticoagulation in Patients with Clinical Stroke Risk Factors After Successful Catheter Ablation of Atrial Fibrillation: The OCEAN Randomized Trial
OCEAN随机试验：房颤导管消融成功后，有临床卒中危险因素的患者是否需要进行持续口服抗凝治疗
LBS.03 瓣膜和冠状动脉前沿试验
北京时间：11月9日 04:15
Early Surgery Versus Conservative Management for Asymptomatic Severe Aortic Stenosis: Final Outcomes of the RECOVERY Trial *
RECOVERY试验最终结果：在无症状重度主动脉瓣狭窄患者中，对比早期手术和保守治疗的疗效*
Biatrial versus Left Atrial Ablation during Mitral Valve Surgery for Persistent Atrial Fibrillation in Rheumatic Heart Disease
ABLATION试验：在风湿性心脏病合并持续性房颤患者进行二尖瓣手术时，对比双心房和左心房消融的疗效
Angiography-derived FFR-Guided Coronary Artery Bypass Grafting for Patients undergoing Valve Surgery with Concomitant Coronary Artery Disease : a Randomized Trial *
FAVOR 4-QVAS随机试验：基于血管造影的血流储备分数（FFR）指导的冠状动脉旁路移植术在合并冠心病的瓣膜手术患者中的应用*
Liberal or Restrictive Transfusion Strategy after General and Vascular Surgery: The Transfusion Trigger after Major Operations in High Cardiac Risk Patients Trial
TOP高心脏风险患者大手术后输血触发试验：普外和血管外科手术后，宽松或限制性输血策略的对比
LBS.04 房颤的心脏代谢与生活方式干预
北京时间：11月9日21:00
Dapagliflozin to Reduce Atrial Fibrillation Burden After Catheter Ablation for Atrial Fibrillation in Patients Without Diabetes or Heart Failure: The DARE-AF Randomized Clinical Trial *
DARE-AF随机临床试验：无糖尿病或心力衰竭患者，在房颤导管消融术后使用达格列净降低房颤负荷*
Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation
META-AF试验：二甲双胍作为房颤导管消融的辅助治疗
The Does Eliminating Coffee Avoid Fibrillation (DECAF) Trial
DECAF试验：停止饮用咖啡能否避免房颤发生
LBS.05 改变临床实践的血压控制试验
北京时间：11月10日 04:30
SSTT (See Sodium To Treat) – Oral KCl Supplementation Safely Reduces Body Na+ Surplus and Blood Pressure in Patients with Arterial Hypertension
SSTT（控钠治疗）试验：口服氯化钾补充剂可安全降低高血压患者的体内钠潴留与血压水平
BETTER-BP– Primary results of the Behavioral Economics Trial to Test Effective Regulation of Blood Pressure
BETTER-BP 试验：基于行为经济学的血压有效调控试验主要结果
GOFRESH – DASH-Patterned Groceries Reduce Blood Pressure: Results from the GoFresh Randomized Clinical Trial
GOFRESH随机临床试验结果：DASH饮食模式的食品可降低血压
Healthy Family Program – A multifaceted family intervention for blood pressure management in rural China: an open label, parallel group, cluster randomized trial *
健康家庭计划：中国农村血压管理的多层面家庭干预：开放标签、平行组、整群随机试验*
LBS.06 缺血性心脏病住院前、住院期间及出院后的干预策略
北京时间：11月10日 21:00
Prehospital treatment with Disaggprotm (Zalunfiban) in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention: Final results of the CELEBRATE trial
CELEBRATE试验最终结果：ST段抬高型心肌梗死（STEMI）患者行直接PCI前，进行Zalunfiban治疗的疗效
Ticagrelor versus Prasugrel in Patients with Diabetes Mellitus and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Randomized Comparison from the TUXEDO-2 Trial
TUXEDO-2随机对照试验结果：在糖尿病合并多支冠状动脉疾病且行经皮冠状动脉介入治疗（PCI）的患者中，进行替格瑞洛与普拉格雷的疗效对比
Efficacy and Safety of Extended Dual Antiplatelet Therapy in Stable Patients With Multivessel Coronary Artery Disease Undergoing Drug-Eluting Stent Implantation (DAPT-MVD): An Investigator-Initiated, Multicenter, Randomized, Open-Label, Assessor-Masked, Superiority Trial
DAPT-MVD研究者发起的多中心优效性随机试验：药物洗脱支架置入术后多支冠脉疾病稳定患者，进行延长双联抗血小板治疗的有效性和安全性
CorCMR – Non-Invasive Endotyping in Patients with Angina and No Obstructive Coronary Artery Disease: A Randomized, Controlled Trial
CorCMR随机对照试验：无非阻塞性冠脉疾病的心绞痛患者的无创内表型分析
LBS.07 心力衰竭治疗成功的秘诀
北京时间：11月10日22:45
A Polypill Strategy for Heart Failure with Reduced Ejection Fraction: The POLY-HF Trial
POLY-HF试验：射血分数降低的心衰的复方制剂治疗策略
Cardiac Allograft Vasculopathy Inhibition with AliRocumab: The CAVIAR Trial
CAVIAR试验：阿利尤单抗抑制心脏移植术后血管病变
Examining the Impact of Medically Tailored Meals vs Produce Supplements Delivered Conditionally vs Unconditionally on Heart Failure Readmissions and Emergency Department Visits: A Randomized Clinical Trial
FOOD-HF随机试验：与有条件/无条件生鲜食品补充剂相比，医学定制膳食对心衰再入院和急诊就诊的影响
Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure (pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial)
SURPASS-CVOT随机临床试验预设分析：在2型糖尿病、动脉粥样硬化性心血管疾病（ASCVD）合并心衰病史的患者中，每周应用一次替尔泊肽与度拉糖肽对心衰结局的影响
注：*已接收未确认的研究
信源：AHA 官网
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
来源：医脉通心内频道
